Ontology highlight
ABSTRACT:
ORGANISM(S): Homo sapiens
SUBMITTER: Katleen De Preter
PROVIDER: E-MTAB-3207 | ArrayExpress | 2015-05-04
REPOSITORIES: ArrayExpress
Lambertz Irina I Kumps Candy C Claeys Shana S Lindner Sven S Beckers Anneleen A Janssens Els E Carter Daniel R DR Cazes Alex A Cheung Belamy B BB De Mariano Marilena M De Bondt An A De Brouwer Sara S Delattre Olivier O Gibbons Jay J Janoueix-Lerosey Isabelle I Laureys Geneviève G Liang Chris C Marchall Glenn M GM Porcu Michael M Takita Junko J Trujillo David Camacho DC Van Den Wyngaert Ilse I Van Roy Nadine N Van Goethem Alan A Van Maerken Tom T Zabrocki Piotr P Cools Jan J Schulte Johannes H JH Vialard Jorge J Speleman Frank F De Preter Katleen K
Clinical cancer research : an official journal of the American Association for Cancer Research 20150324 14
Activating ALK mutations are present in almost 10% of primary neuroblastomas and mark patients for treatment with small-molecule ALK inhibitors in clinical trials. However, recent studies have shown that multiple mechanisms drive resistance to these molecular therapies. We anticipated that detailed mapping of the oncogenic ALK-driven signaling in neuroblastoma can aid to identify potential fragile nodes as additional targets for combination therapies.To achieve this goal, transcriptome profiling ...[more]